A mutation in β‐tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel‐resistant prostate cancer cell line
Takahito Hara(Takeda (Japan)), Masuo Yamaoka, Kazutaka Ushio(Takeda (Japan)), Hideo Araki(Hiroshima University), Yumi Imai(University of Iowa), Jin Kouno(Takeda (Japan)), Masahiko Hattori(Takeda (Japan)), Yukiko Hikichi(Takeda (Japan)), Mayumi Nishiwaki(Takeda (Japan))
Cited by 38
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Cl–π interactions in protein–ligand complexes
|Protein Science|2008|213
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116